Journal for ImmunoTherapy of Cancer
Featured Publications
Guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma were recently published as part of the Society for Immunotherapy of Cancer’s (SITC) Cancer Immunotherapy Guidelines series. These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
Based on another SITC-led initiative, the SITC Immune Biomarkers Task Force recently published Volume I and Volume II of the guideline document, ‘Validation of biomarkers to predict response to immunotherapy in cancer’. Driven by the first Working Group (WG1) of the Immune Biomarkers Task Force, which includes representatives from academia, clinical medicine, government and industry, this report is the first to make evidence-based recommendations concerning the development, validation and regulation of biomarkers developed to predict response to cancer immunotherapy.
Based on another SITC-led initiative, the SITC Immune Biomarkers Task Force recently published Volume I and Volume II of the guideline document, ‘Validation of biomarkers to predict response to immunotherapy in cancer’. Driven by the first Working Group (WG1) of the Immune Biomarkers Task Force, which includes representatives from academia, clinical medicine, government and industry, this report is the first to make evidence-based recommendations concerning the development, validation and regulation of biomarkers developed to predict response to cancer immunotherapy.
Articles
CASE REPORTClinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Kathryn E. Beckermann, et al
CASE REPORTInterstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Julia Escandon, et al
COMMENTARYPotassium channels of T lymphocytes take center stage in the fight against cancer
Laura Conforti
COMMENTARYIt’s a long way to the top (if you want to personalize immunotherapy)
Sarah Haebe and Oliver Weigert
RESEARCH ARTICLERadiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al
REVIEWUnfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer
Juan R. Cubillos-Ruiz, et al
View all articles >
.png)
No hay comentarios:
Publicar un comentario